Clinical trials
Completed Phase 1 Anemia, Refractory, with Excess of Blasts trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
48 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 7 |
| 2001 | 1 |
| 2002 | 4 |
| 2003 | 2 |
| 2004 | 5 |
| 2005 | 6 |
| 2006 | 3 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 2 |
| 2012 | 1 |
| 2019 | 1 |
| 2020 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 48 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 9 |
| Fred Hutchinson Cancer Center | 5 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 5 |
| Memorial Sloan Kettering Cancer Center | 4 |
| M.D. Anderson Cancer Center | 3 |
| Vion Pharmaceuticals | 3 |
| Case Comprehensive Cancer Center | 2 |
| Dana-Farber Cancer Institute | 2 |
| AbbVie (prior sponsor, Abbott) | 1 |
| Alaunos Therapeutics | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Anemia, Refractory, with Excess of Blasts | 48 |
| Leukemia, Myeloid, Acute | 33 |
| Leukemia | 28 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 27 |
| Leukemia, Myelomonocytic, Chronic | 26 |
| Myelodysplastic Syndromes | 26 |
| Blast Crisis | 18 |
| Congenital Abnormalities | 18 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 16 |
| Myeloproliferative Disorders | 16 |
Trials
Showing 1 to 25 of 48. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.